MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-13-2025
GeoVax Labs Operating Income 2011-2026 | GOVX
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income GeoVax Labs
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -26.7 M | -14 M | -18.7 M | -2.82 M | -2.37 M | -2.56 M | -2.17 M | -3.27 M | -2.69 M | -2.74 M | -2.29 M | -2.14 M | -2.35 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -2.14 M | -26.7 M | -6.53 M |
Quarterly Operating Income GeoVax Labs
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -6.37 M | -5.42 M | -5.41 M | - | -5.85 M | -5.06 M | -5.88 M | - | -8.6 M | -6.18 M | -4.27 M | - | -3.97 M | -2.24 M | -2.43 M | - | -1.95 M | -1.49 M | -1.56 M | - | -436 K | -448 K | -595 K | - | -426 K | -654 K | -702 K | - | -667 K | -638 K | -623 K | - | -590 K | -518 K | -549 K | - | -465 K | -576 K | -1.3 M | - | -621 K | -678 K | -702 K | - | -515 K | -681 K | -702 K | - | -191 K | -527 K | -698 K | - | -298 K | -499 K | -731 K | - | -376 K | -212 K | -607 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -191 K | -8.6 M | -1.86 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M |  Germany |
 |
Autolus Therapeutics plc
AUTL
|
-241 M | $ 1.82 | -4.85 % | $ 464 M |  Britain |
 |
Adagene
ADAG
|
-36 M | $ 1.65 | - | $ 92.9 M |  China |
 |
Arrowhead Pharmaceuticals
ARWR
|
98.3 M | $ 64.9 | -0.15 % | $ 8.68 B |  USA |
 |
AgeX Therapeutics
AGE
|
-9.89 M | - | -10.17 % | $ 12.2 K | USA |
 |
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M |  France |
 |
Biogen
BIIB
|
7.04 B | $ 187.4 | 0.75 % | $ 27.3 B | USA |
 |
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-209 M | - | - | $ 1.01 B | USA |
 |
Albireo Pharma
ALBO
|
-123 M | - | -0.23 % | $ 916 M | USA |
 |
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Alpine Immune Sciences
ALPN
|
-58.1 M | - | - | $ 2.17 B | USA |
 |
BioXcel Therapeutics
BTAI
|
-67.2 M | $ 1.98 | -1.0 % | $ 5.02 M | USA |
 |
AlloVir
ALVR
|
-65.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
CASI Pharmaceuticals
CASI
|
-41.8 M | $ 1.04 | -2.34 % | $ 142 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-33.3 M | - | -11.43 % | $ 502 K | USA |
 |
Catalyst Biosciences
CBIO
|
-67.2 M | $ 10.74 | -2.1 % | $ 707 M | USA |
 |
Applied Molecular Transport
AMTI
|
-127 M | - | - | $ 10.1 M | USA |
 |
Aravive
ARAV
|
-70.8 M | - | -13.39 % | $ 1.45 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
-624 M | - | -6.81 % | $ 3.04 B | USA |
 |
Athersys
ATHX
|
-87.1 M | - | 3.77 % | $ 22.4 M | USA |
 |
Avenue Therapeutics
ATXI
|
-11.3 M | - | -52.27 % | $ 4.45 M | USA |
 |
AIkido Pharma
AIKI
|
-11.5 M | - | 1.93 % | $ 17.4 M | USA |
 |
Celldex Therapeutics
CLDX
|
-195 M | $ 27.0 | -1.28 % | $ 1.74 M | USA |
 |
Cellectis S.A.
CLLS
|
-131 M | $ 4.42 | -1.34 % | $ 116 M | France |
 |
Ascendis Pharma A/S
ASND
|
-452 M | $ 201.94 | -3.26 % | $ 5 B |  Danmark |
 |
BioVie
BIVI
|
-18.1 M | $ 1.27 | -2.31 % | $ 1.88 M | USA |
 |
ARCA biopharma
ABIO
|
-88.1 M | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
-16.7 M | - | 4.01 % | $ 150 M |  Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
-140 M | - | -15.15 % | $ 60.3 M | Britain |
 |
BioNTech SE
BNTX
|
15.3 B | $ 99.81 | 0.97 % | $ 27.2 B | Germany |
 |
AVROBIO
AVRO
|
10.2 M | - | 1083.1 % | $ 745 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
205 M | $ 27.75 | 0.02 % | $ 1.34 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-8.13 M | $ 4.14 | -3.72 % | $ 9.01 B |  Israel |
 |
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
-24.6 M | - | 2.71 % | $ 14 M | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
-704 M | $ 11.13 | -2.02 % | $ 720 M | USA |
 |
BioDelivery Sciences International
BDSI
|
37.1 M | - | -4.8 % | $ 255 M | USA |
 |
Axon Enterprise
AXON
|
58.5 M | $ 633.45 | 3.34 % | $ 48 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-37.5 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
-7.83 M | $ 2.64 | -0.75 % | $ 16.6 M | USA |
 |
BeiGene, Ltd.
BGNE
|
-568 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
AstraZeneca PLC
AZN
|
1.06 B | $ 94.65 | 0.68 % | $ 96.9 B | Britain |
 |
Bellicum Pharmaceuticals
BLCM
|
-27 M | - | -9.72 % | $ 5.89 M | USA |